[1]
Arora, MD, S., Setnik, PhD, B., Drass, MD, M., Hudson, MD, J.D., Clemmer, MS, R., Meisner, PharmD, P., Pixton, MS, G.C., Goli, MD, V. and Sommerville, MD, K.W. 2014. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. Journal of Opioid Management. 10, 6 (Nov. 2014), 423–436. DOI:https://doi.org/10.5055/jom.2014.0239.